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Abstract
Background: Although PPARγ antagonists have shown considerable pre-clinical efficacy, recent
studies suggest PPARγ ligands induce PPARγ-independent effects. There is a need to better define
such effects to permit rational utilization of these agents.
Methods: We have studied the effects of a range of endogenous and synthetic PPARγ ligands on
proliferation, growth arrest (FACS analysis) and apoptosis (caspase-3/7 activation and DNA
fragmentation) in multiple prostate carcinoma cell lines (DU145, PC-3 and LNCaP) and in a series
of cell lines modelling metastatic transitional cell carcinoma of the bladder (TSU-Pr1, TSU-Pr1-B1
and TSU-Pr1-B2).
Results: 15-deoxy-prostaglandin J2 (15dPGJ2), troglitazone (TGZ) and to a lesser extent
ciglitazone exhibited inhibitory effects on cell number; the selective PPARγ antagonist GW9662 did
not reverse these effects. Rosiglitazone and pioglitazone had no effect on proliferation. In addition,
TGZ induced G0/G1 growth arrest whilst 15dPGJ2 induced apoptosis.
Conclusion: Troglitazone and 15dPGJ2 inhibit growth of prostate and bladder carcinoma cell lines
through different mechanisms and the effects of both agents are PPARγ-independent.
Background
The transcription factor peroxisome proliferator-activated
receptor gamma (PPARγ) has sparked significant interest
in the cancer field owing to observations of increased
expression in several diverse carcinomas [1-4]. Moreover,
endogenous and synthetic PPARγ agonists elicit notable
growth inhibitory effects in vitro and in vivo (colon, breast
and prostate carcinomas) and are capable of preventing
metastasis [2,5-9]. PPARγ is a member of the family of
nuclear hormone receptors and exists as two isoforms
(PPARγ1 and PPARγ2) encoded by multiple transcript var-
iants [10]. PPARγ1 is the predominant isoform in humans
and is highly expressed in adipose tissue and liver [8,10].
Historically, PPARγ is recognized as a critical transcription
factor in the regulation of adipocyte differentiation and
genes involved in energy storage and utilisation [11], and
PPARγ agonists (rosiglitazone, pioglitazone) are currently
in clinical use for the treatment of Type II diabetes [12].
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BMC Cancer 2006, 6:53 http://www.biomedcentral.com/1471-2407/6/53Several high affinity ligands are routinely used to investi-
gate PPARγ-mediated effects, including the family of syn-
thetic thiazolidinedione ligands (rosiglitazone, RGZ;
pioglitazone, PGZ; ciglitazone, CGZ; troglitazone, TGZ;
listed from highest to lowest affinity (Kd 30–750 nM) for
PPARγ) and the endogenous ligand 15-deoxy-prostaglan-
din J2 (15dPGJ2), a metabolite of prostaglandin D2
(Kd~300 nM) [13,14]. While previous studies demon-
strate that some PPARγ ligands inhibit growth of multiple
carcinoma cell lines [6,15-17], many reports demonstrate
that PPARγ ligand-mediated growth inhibition can vary
depending on the cancer type. In astroglioma, colorectal,
and hepatocellular carcinoma, as well as in astrocytes and
preadipocytes, growth inhibition can be limited to a par-
ticular member of the thiazolidinedione family [18-21],
and has been shown to be selective for the endogenous
PPARγ ligand, 15dPGJ2, over members of the thiazolidin-
edione family [22]. Indeed, even within a carcinoma type,
growth inhibition induced by PPARγ ligands can be cell
line specific [23]. In addition, studies utilising the irrevers-
ible PPARγ-selective antagonist GW9662, have revealed
PPARγ-dependent and -independent mechanisms of
growth inhibition [21,24-26], further highlighting the
incongruity of responsiveness between cancer types.
The high incidence of prostate and bladder carcinoma
poses a significant health risk for men, including Austral-
ian and North American males Interestingly, the expres-
sion of PPARγ is increased with grade and advancement of
disease [1,3]. In clinical trials of patients with advanced
prostate cancer, treatment with TGZ has resulted in pro-
longed stabilisation of prostate specific antigen (PSA) lev-
els [28,29]. Although genetic deficiency of PPARγ does not
alter the development of experimental prostate cancer
[30], individual PPARγ ligands have been shown to
inhibit in vitro cellular proliferation of both human blad-
der and prostate carcinoma cell lines [1,2,31-34]. In pros-
tate carcinoma cell lines the antiproliferative effects of
these agonists have also been associated with morpholog-
ical changes indicative of terminal differentiation [34]
and a less malignant phenotype [2].
The antineoplastic properties of the thiazolidinedione lig-
ands have offered promise in clinical and pre-clinical
studies of prostate carcinoma, but are yet to be fully char-
acterised in bladder carcinoma. In other cancer types, it is
becoming evident that growth inhibition can be ligand
dependent, and cannot always be attributed to PPARγ acti-
vation. These studies also illustrate that the specific PPARγ
agonist utilised critically determines the outcome. In this
study we have utilized a broad range of PPARγ agonists
and the PPARγ-selective antagonist GW9662, to examine
the effect of PPARγ activation in prostate and bladder car-
cinoma cell lines.
Methods
Cell lines and reagents
TSU-Pr1, DU145, PC-3 and LNCaP cell lines were
obtained from Dr Dan Djakiew, Georgetown University,
USA [35]; TSU-Pr1-B1 and TSU-Pr1-B2 showing increas-
ing metastatic potential were generated in our laboratory
by in vivo selection to bone ; HL60 cell line was obtained
from the Peter McCallum Cancer Centre, Australia; 3T3-
L1 cell line was obtained from the American Type Culture
Collection (Rockville, MD). All cell lines were cultured in
DMEM (Gibco, Australia) supplemented with 10% foetal
bovine serum (FBS, JRH Biosciences, Australia). Rosiglita-
zone (RGZ), troglitazone (TGZ), pioglitazone (PGZ), cigl-
itazone (CGZ), 15dPGJ2 and GW9662 were purchased
from Sapphire Biosciences (Australia) and were dissolved
in dimethylsulfoxide (DMSO) (Sigma, Australia). Doxo-
rubicin (Dox) and Sulforhodamine B (SRB) were pur-
chased from Sigma.
qRT-PCR
Total RNA was isolated using RNeasy Mini Kit (Qiagen,
Australia) as per the manufacturer's instructions. RNA was
reverse transcribed (Superscript II; Invitrogen, Australia)
to cDNA using random hexamers (Invitrogen, Australia).
Quantitative RT-PCR was performed on an ABI Prism
5700 Sequence Detection System (Perkin-Elmer Applied
Biosystems; Australia) in 10 mM Tris-HCl pH 8.0, 2.5 mM
Mg(C2H3O2)2, 50 mM KCl, 200 µM dNTPs, 1/40,000
dilution of SYBR Green I (Molecular Probes; Eugene, Ore-
gon USA), 1 µg/ml 6-carboxy-X-rhodamine (6-ROX;
Molecular Probes), 8% DMSO, 200 nM primers and
0.625 U AmpliTaq Gold polymerase (Applied Biosys-
tems) per 25 µL reaction. Levels of PPARγ1,3 transcript
variants (NM_138712 and NM_138711; primers: 5'-
CCATTTTCTCAAACGAGAGTCAGCCTTT-3' and 5'-
CTCTGTGTCAACCATGGTCATTTCGTT-3'), PPARγ2 tran-
script variant (NM_015869 ; primers: 5'-GATGTCTT-
GACTCATGGGTGTATTCACAAA-3' and 5'-
GTTTGCAGACAGTGTATCAGTGAAGGAA-3') and
PPARγ4 transcript variant (NM_005037; primers: 5'-
CGCCGTGGCCGCAGAAAT-3' and 5'- GATCCACG-
GAGCTGATCCCAAA-3') were measured. Each primer set
gave rise to predicted sized amplicons of 55, 202 and 80
bp respectively. L32 (NM_000994; primers: 5'-CAGGGT-
TCGTAGAAGATTCAAGGG-3' and 5'-CTTGGAGGAAA-
CATTGTGAGCGATC-3'; amplicon: 190 bp), a ribosome
associated protein, was used as a housekeeping gene to
normalise all samples as previously described [36]. All
reactions were performed in quadruplicate. PCR condi-
tions were 95°C, 10 min followed by 50 cycles of reaction
at 95°C, 15 s, 60°C, 1 min. Specificity of PCR products
was determined by dissociation curve analysis as recom-
mended by the manufacturer (ABI) and products were
confirmed to be single bands by visualisation following
gel electrophoresis. The comparative CT method was vali-Page 2 of 13
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Detection of PPARγ isoforms in bladder (TSU-Pr1, TSU-Pr1-B1, TSU-Pr1-B2) and prostate (DU145, PC-3 and LNCaP) cell linesFigure 1
Detection of PPARγ isoforms in bladder (TSU-Pr1, TSU-Pr1-B1, TSU-Pr1-B2) and prostate (DU145, PC-3 and 
LNCaP) cell lines. PPARγ1 (encoded by PPARγ variants 1, 3 and 4) and PPARγ2 isoforms were measured by qRT-PCR. ∆CT 
values were derived by normalisation to levels of the L32 housekeeping gene in each cDNA sample. * Significantly different to 
TSU-Pr1 (p < 0.001), # significantly different to TSU-Pr1 and LNCaP, (p < 0.01), δ significantly different to DU145 (p < 0.03) 
(unpaired t test)
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BMC Cancer 2006, 6:53 http://www.biomedcentral.com/1471-2407/6/53dated by assessing the amplification efficiency of each of
the primer sets listed above in a single PCR run as per the
manufacturer's recommendations (ABI).
Proliferation analysis
Cell number was estimated using the SRB assay. Cells
were seeded in 96-well plates at a starting density of 1 ×
103 cells/well and treated with PPARγ ligand or control
vehicle (0.2 % DMSO) in the presence or absence of
GW9662 (10 µM) the following day. At days 0, 1, 3, 5, 7
and 9, cells were fixed with 25 µL cold (4°C) 50% trichlo-
roacetic acid for 1 hr at 4°C. Cells were stained with 100
µL SRB (0.4 g/100 mL in 1% acetic acid) for 15 minutes at
room temperature (RT), washed with 1% acetic acid and
left to dry overnight. Bound SRB was resuspended in 10
mM Tris base (pH 10.5) and read at 550 nm on a Labsys-
tems Multiskan RC spectrophotometer.
Cell cycle analysis
Cells were seeded in six 10 cm dishes at varying densities
according to ligand treatment (1 × 105 cells/plate; con-
trol, RGZ 10 µM, TGZ 50 µM and 15dPGJ2 5.6 µM and 3
× 105 cells/plate; TGZ 100 µM and 15dPGJ2 10 µM) and
after 24 hrs media was replaced with fresh media contain-
ing the specific PPARγ ligand treatment or control vehicle
(0.1% DMSO) for 72 hrs. Floating and adherent cells were
combined, pelleted (400 g), washed in phosphate buff-
ered saline (PBS) and resuspended in 200 µL PBS contain-
ing 0.1% FBS. The cell suspension was diluted 10-fold in
ice-cold 90% ethanol and placed at -20°C for 15 minutes.
Cells were then washed twice with 0.1% FBS in PBS and
resuspended in RNase (2 µg/mL) (Roche, Australia) and 5
mg/mL Propidium Iodide (Sigma). Flow cytometric anal-
ysis of DNA content was performed using a FACScalibar
(Becton Dickinson) with Cellquest software (Becton Dick-
inson) and analysed using Modfit cell cycle analysis soft-
ware (Verity Software House, Maine) as previously
described
Determination of DNA fragmentation
DNA was extracted using the Apoptotic DNA Ladder Kit
(Roche), according to the manufacturer's instructions.
Briefly, cells were seeded in 10 cm dishes and after 24 hrs
media was replaced with fresh media containing the spe-
cific PPARγ ligand, doxorubicin (Dox, 1 µM) or control
vehicle (0.1% DMSO) for 72 hrs. Floating and adherent
cells were combined, lysed, applied to a column, and the
DNA eluted. Samples were treated with RNase (2 µg/mL,
15 mins, RT). DNA was run on a 1% agarose gel contain-
ing ethidium bromide and visualised on a UV transillumi-
nator (Promega, Australia).
Caspase activation
Levels of active caspase-3/7 after ligand treatment were
measured using the CaspaTag™ Caspase-3/7 In situ Assay
Kit (Chemicon International, Australia), according to the
manufacturer's instructions. Briefly, 1 × 106cells (Control,
RGZ 10 µM, TGZ 50 µM and 15dPGJ2 5.6 µM) and 3 ×
106cells (TGZ 100 µM, 15dPGJ2 10 µM, Dox 1 µM) were
seeded in 15 cm dishes and treated for 48 hrs to induce
apoptosis. Cells were then exposed to a carboxyfluores-
cein-labeled fluoromethyl ketone inhibitor of caspase-3/7
(FAM-DEVD-FMK) and transferred to a microtiter plate.
Levels of active caspase-3/7 were measured by reading the
fluorescence of each microwell with excitation (485 nm)
and emission (535 nm) wavelengths using a Wallac 1200
spectrophotometer.
Statistical analysis
Results are expressed as mean ± standard error (SEM)
from 2–3 experiments performed in triplicate. Unpaired t
test or ANOVA followed by the Dunnett post test were
used to determine statistical significance. P < 0.05 was
considered significant.
Results
Levels of PPARγ mRNA in bladder and prostate cell lines
We examined the expression of PPARγ in TSU-Pr1 and
sublines with increasing metastatic potential (Figure 1A).
PPARγ1,3, PPARγ2 and PPARγ4 transcript variants were
detected in all cell lines. PPARγ1,3 was expressed at the
highest levels in all three cell lines, followed by PPARγ4
(these transcript variants detect PPARγ isoform 1).
PPARγ2 (PPARγ isoform 2) was expressed at the lowest
level in all three cell lines. Interestingly, the levels of both
PPARγ isoforms were significantly up-regulated in the
more metastatic sublines TSU-Pr1-B1 and TSU-Pr1-B2
compared to TSU-Pr1 (with the exception of the PPARγ4
levels in TSU-Pr1-B1 compared to TSU-Pr1).
The prostate cell lines DU145, PC-3 and LNCaP were also
examined for PPARγ expression and compared to expres-
sion levels in TSU-Pr1 (Figure 1B). The levels of all tran-
script variants were similar in TSU-Pr1 and LNCaP cell
lines with PPARγ1,3 expressed at the highest level and
PPARγ2 at the lowest level. All transcript variants were
expressed at significantly higher levels in DU145 and PC-
3 cell lines compared to TSU-Pr1 and LNCaP cell lines. In
addition, the expression level of PPARγ4 and PPARγ2 were
significantly higher in DU145 cells compared to the PC-3
cell line.
Thiazolidinedione ligands and 15dPGJ2 decrease cell 
number in bladder cell line TSU-Pr1
The effects of TGZ (50 and 100 µM), CGZ (40 µM), RGZ
(10 µM), PGZ (20 µM) and 15dPGJ2 (5.6 and 10 µM) on
the TSU-Pr1 bladder carcinoma cell line were examined in
the presence or absence of the highly selective PPARγ
antagonist GW9662 (10 µM). This concentration of
GW9662 inhibited TGZ- and RGZ-induced lipid accumu-Page 4 of 13
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Effect of PPARγ ligands on TSU-Pr1 cell numberFigure 2
Effect of PPARγ ligands on TSU-Pr1 cell number. Cells were treated with ligand either alone or in the presence of 10 
µM GW9662 at Day 0. A, Troglitazone (100 µM; TGZ) and ciglitazone (40 µM; CGZ). B, Rosiglitazone (10 µM; RGZ) and piogl-
itazone (20 µM; PGZ). C, 15-deoxy-prostaglandin J2 (15dPGJ2) 5.6 µM and 10 µM. Values are mean ± SEM of 2–3 experiments 
performed in triplicate expressed as percent control. Statistical significance * P < 0.01 (ANOVA followed by Dunnett post 
test).
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BMC Cancer 2006, 6:53 http://www.biomedcentral.com/1471-2407/6/53lation in differentiating NIH3T3-L1 cells (data not
shown). The effects of ligand treatment on cell number
were determined at days 0, 1, 3, 5, 7 and 9. TGZ (100 µM)
induced a marked inhibition of cell number (75% inhibi-
tion at day 3), which was sustained throughout the time
course of the experiment (Figure 2A). TGZ had no effect
on cell number at a lower dose (50 µM) (data not shown).
CGZ caused a small decrease (approximately 25%) in cell
number at day 1, which subsided to a modest 10–15 %
inhibition over days 3 to 9 (Figure 2A). The more potent
PPARγ ligands RGZ and PGZ did not affect TSU-Pr1 cell
number (Figure 2B). The endogenous PPARγ ligand
15dPGJ2 exhibited a potent and sustained effect on cell
number at 10 µM (92% inhibition at day 3). At a lower
dose (5.6 µM), 15dPGJ2 initially inhibited cell number
(60% at day 3), however this effect was no longer evident
by day 5 (Figure 2). It is possible that 15dPGJ2 is either
breaking down or being metabolised such that the 5.6 µM
treatment is unable to maintain suppression of prolifera-
tion over the course of the experiment. The growth inhib-
itory effects of TGZ, CGZ and 15dPGJ2 on cell number
were not reversed by 10 µM GW9662 (Figure 2A–C). Fur-
thermore, at doses ranging from 1 to 100 µM, GW9662
had no effect on TGZ-induced growth inhibition of TSU-
Pr1 cells (data not shown).
Thiazolidinedione ligands and 15dPGJ2 decrease cell 
number in TSU-Pr1-B1 and TSU-Pr1-B2 sublines
The effects of thiazolidinedione agonists, 15dPGJ2 and
GW9662 were examined in the TSU-Pr1 sublines that
have significantly increased expression of PPARγ. TGZ (10
and 100 µM), CGZ (40 µM), RGZ (10 µM), 15dPGJ2 (1
and 10 µM) were applied to the cells in the presence or
absence of GW9662 (10 µM). Cell number was deter-
mined over a 9 day period and the results from Day 5 have
been represented (Figure 3). As was observed in TSU-Pr1
Effect of PPARγ ligands on cell number of TSU-Pr1/TSU-Pr1-B1/TSU-Pr1-B2 series day 5Figure 3
Effect of PPARγ ligands on cell number of TSU-Pr1/TSU-Pr1-B1/TSU-Pr1-B2 series day 5. TSU-Pr1, TSU-Pr1-B1 
and TSU-Pr1-B2 cells were treated with control (0.2% DMSO), GW9662 (10 µM), troglitazone (10 and 100 µM; TGZ), ciglita-
zone (40 µM; CGZ), rosiglitazone (10 µM; RGZ) and 15-deoxy-prostaglandin J2 (1 and 10 µM; 15dPGJ2) in the presence or 
absence of antagonist GW9662 (10 µM) at day 0. Values are mean ± SEM from Day 5. * All cell lines significantly different to 
the respective controls, # TSU-Pr1 and TSU-Pr1-B2 significantly different to the respective controls (unpaired t test).
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Effect of PPARγ ligands on cell number of prostate cell lines at day 5Figure 4
Effect of PPARγ ligands on cell number of prostate cell lines at day 5. Cells were treated with control (0.2% DMSO), 
troglitazone (100 µM; TGZ), ciglitazone (40 µM; CGZ), rosiglitazone (10 µM; RGZ), pioglitazone (20 µM; PGZ) and 15-deoxy-
prostaglandin J2 (5.6 and 10 µM; 15dPGJ2) in the presence or absence of antagonist GW9662 (10 µM) at day 0. A, DU145 cells; 
B, PC-3 cells; C, LNCaP cells Values are mean ± SEM of two experiments performed in triplicate expressed as percent control. 
No significant differences were detected following GW9662 treatment for any agent. Statistical significance compared to con-
trol * P < 0.01, #P < 0.05 (ANOVA followed by Dunnett post test).
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Effect of PPARγ ligands on cell cycle in TSU-Pr1 and PC-3 cellsFigure 5
Effect of PPARγ ligands on cell cycle in TSU-Pr1 and PC-3 cells. Cells were cultured for 3 days with control (0.1% 
DMSO), troglitazone (50 and 100 µM; TGZ), 15-deoxy-prostaglandin J2 (5.6 and 10 µM; 15dPGJ2) or rosiglitazone (10 µM; 
RGZ). The effect of these ligands on the proportion of cells in each phase of the cell cycle was determined. Data shown is rep-
resentative of two experiments.
G1 G2 S Apoptotic
Tsu-Pr1 Control 47.64 3.41 48.94 0.43
RGZ 10µM 48.57 6.41 45.01 5.66
TGZ 50µM 85.88 0.00 14.12 1.44
TGZ 100µM 95.68 0.00 4.32 1.63
15dPGJ2 5.6µM 52.09 1.15 46.75 1.54
15dPGJ2 10µM 46.68 5.08 48.24 11.00
PC3 Control 60.12 3.84 36.04 2.04
RGZ 10µM 65.68 3.06 31.26 1.05
TGZ 50µM 87.27 3.02 9.71 2.29
TGZ 100µM 91.19 1.58 7.23 1.21
15dPGJ2 5.6µM 74.62 3.97 21.41 7.17
15dPGJ2 10µM 53.01 14.06 32.93 22.59
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Effect of PPARγ ligands on apoptosisFigure 6
Effect of PPARγ ligands on apoptosis. The effect of PPARγ ligands on apoptosis was measured using caspase-3/7 activation 
(A) and DNA fragmentation (B). A, HL60 and TSU-Pr1 cells were treated with either control (0.1% DMSO), Doxorubicin (0.5 
or 1 µM; Dox). TSU-Pr1 cells were also treated with troglitazone (50 and 100 µM; TGZ), 15-deoxy-prostaglandin J2 (5.6 and 10 µM; 15dPGJ2) or rosiglitazone (10 µM; RGZ) for 48 hrs. Levels of activated caspase-3/7 were determined by fluorescence 
measured at 535 nm. Values are mean ± SEM of 2 experiments performed in triplicate. B, HL60 and TSU-Pr1 cells were 
treated with Doxorubicin (1 µM; Dox), troglitazone (100 µM; TGZ), 15-deoxy-prostaglandin J2 (10 µM; 15dPGJ2) or rosiglita-
zone (10 µM; RGZ) for 72 hrs. DNA was extracted and run on a 1 % agarose gel. Statistical significance * P < 0.01, different to 
TSU-Pr1 control (ANOVA followed by Dunnett post test).
BMC Cancer 2006, 6:53 http://www.biomedcentral.com/1471-2407/6/53cells (Figure 2 and Figure 3), TGZ (100 µM) and 15dPGJ2
(10 µM) dramatically inhibited growth in TSU-Pr1-B1
and TSU-Pr1-B2 cells. There was no difference in the
extent of growth inhibition caused by these ligands
between the three cell lines despite varying PPARγ expres-
sion levels. Again these effects were not reversed by
GW9662.
Thiazolidinedione ligands and 15dPGJ2 decrease cell 
number in prostate cell lines
The effects of thiazolidinedione agonists, 15dPGJ2 and
PPARγ antagonist GW9662 were further examined in a
series of prostate cell lines (DU145, PC-3 and LNCaP).
LNCaP cells were plated at a higher density (3 × 103 cells/
well) due to their slower mitotic rate. The effects of these
ligands have been shown at day 5, when maximal inhibi-
tion was observed (Figure 4). Patterns of growth inhibi-
tion similar to those seen in TSU-Pr1 cells (Figure 2 and
Figure 3) were observed in all prostate carcinoma cell
lines. TGZ (100 µM) and 15dPGJ2 (10 µM) treatment had
a marked inhibitory effect on cell number (Figure 4A–C).
PC-3 cells were more sensitive to the 15dPGJ2 treatment
as evidenced by a significant inhibition at the lower dose
of 15dPGJ2 (5.6 µM) (Figure 4B), an effect which was not
observed in either DU145 (Figure 4A) or LNCaP cell lines
(Figure 4C) and only partially seen with TSU-Pr1 (Figure
2 and Figure 3). All prostate carcinoma cell lines showed
a significant inhibition of cell number in response to CGZ
treatment at day 5, an effect that was most pronounced in
LNCaP cells (Figure 4) whereas only a slight effect of CGZ
was noted in TSU-Pr1 cells (Figure 2 and Figure 3). As
observed in TSU-Pr1 cells, the inhibitory effects exerted by
these agonists were not reversed by the addition of the
PPARγ antagonist GW9662 (Figure 4) and the thiazolidin-
edione compounds with the highest affinity for PPARγ
(RGZ and PGZ) showed no effect (data not shown).
TGZ and 15dPGJ2 exert differential effects on cell cycle 
and apoptosis
Given the similar response profiles to the different PPARγ
ligands in all bladder and prostate carcinoma cell lines
examined, the effect of TGZ, 15dPGJ2 and RGZ on cell
cycle regulation was examined in more detail in TSU-Pr1
and PC-3 cell lines (Figure 5). TGZ produced a dose-
dependent cell cycle arrest in G1 phase both TSU-Pr1 and
PC-3 cell lines. In contrast to this 15dPGJ2 dose depend-
ently increased the proportion of subG1 cells, accompa-
nied by an arrest in G2 phase in TSU-Pr1 and PC-3 cell
lines. The effect of 5.6 uM 15dPGJ2 on the proportion of
cells in the subG1 peak was more marked in PC-3 cells. A
G1 arrest was observed in response to RGZ treatment in
both cell lines. In addition a small increase in the propor-
tion of cells in the subG1 peak was observed in response
to RGZ treatment in TSU-Pr1 cells.
TGZ and 15dPGJ2 alter levels of caspase-3/7 activation 
and DNA fragmentation
Doxorubicin (Dox) induces apoptosis in the human mye-
loid leukaemia cell line HL60 [37] and was used as a pos-
itive control for both caspase-3/7 activation and DNA
fragmentation (Figure 6A and 6B). Induction of apoptosis
was investigated by measurement of levels of caspase-3/7
activation after PPARγ ligand treatment in TSU-Pr1 (Fig-
ure 6A) and PC-3 (data not shown) cell lines. Both Dox (1
µM) and 15dPGJ2 (10 µM) induced significant caspase-3/
7 activation in TSU-Pr1 (Figure 6A) and PC-3 cells, while
TGZ (100 µM) induced a small but significant increase in
caspase-3/7 activation in PC-3 cells. DNA fragmentation
was examined to further investigate the induction of
apoptosis. Dox induced DNA fragmentation in the HL60
and TSU-Pr1 cell lines (Figure 6B) after 72 hours of ligand
treatment. DNA laddering was induced by 15dPGJ2 (10
µM) treatment in TSU-Pr1 (Figure 6B) and PC-3 (data not
shown) cell lines. TGZ (100 µM) did not induce DNA lad-
dering in any sample examined. RGZ (10 µM) did not
induce measurable caspase 3/7 activation or DNA ladder-
ing in either TSU-Pr1 (Fig 6) or PC-3 (data not shown) cell
lines suggesting that the increase in the proportion of cells
in the subG1peak of RGZ (10 µM) in TSU-Pr1 cells
observed in Fig 5 may have been due to cells undergoing
necrosis.
Discussion
Thiazolidinedione ligands have been shown to inhibit the
growth of multiple cancer cell lines [2,6,17,38], however
it is becoming apparent that these antineoplastic effects
cannot always be attributed to PPARγ activation. Reports
of PPARγ ligand induced growth inhibition demonstrate
three important points: i) Growth inhibition can be spe-
cific to members of the thiazolidinedione family [18,19]
ii) Growth inhibition can be selective for an endogenous
PPARγ ligand compared to synthetic ligand [22], iii)
PPARγ ligand mediated growth inhibition is PPARγ-inde-
pendent in some cancer types [24,39]. Clearly the
response to PPARγ ligands and the involvement of PPARγ
in these effects differs widely amongst carcinoma types
and thus each carcinoma type must be specifically exam-
ined. The current study investigated the response to an
array of thiazolidinedione agonists and an endogenous
PPARγ agonist, 15dPGJ2, in bladder and prostate carci-
noma cell lines of differing metastatic potential. In addi-
tion we have utilised the selective PPARγ antagonist
GW9662 to elucidate the involvement of this receptor in
the growth inhibitory effects observed.
We detected profound growth inhibition in response to
TGZ and 15dPGJ2 in all bladder and prostate carcinoma
cell lines. These results are consistent with the growth
inhibitory effects reported by Yoshimura et al. albeit that
in our hands 15dPGJ2 generally exerted more potentPage 10 of 13
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comparatively less potent. The different assays or vehicle
utilised may account for these observations. We also
found that RGZ and PGZ did not inhibit cell number in
the bladder or prostate carcinoma cell lines used in this
study. We confirmed that at the dose used in this study,
RGZ was capable of inducing adipogenesis in NIH3T3-L1
cells. These findings are similar to the little or no effect on
cellular growth exerted by RGZ and PGZ in other cancer
systems [18,40]. Our results demonstrate that the known
affinities of PPARγ ligands for PPARγ did not predict their
relative potency. In other studies using prostate cancer cell
lines, RGZ has been shown to inhibit cell number in PC-
3 cells [2,34,41]. From our study it is clear that the thiazo-
lidinedione family are not acting through PPARγ. When
the mechanism is elucidated it will be important to inves-
tigate the activity of the relevant pathway in the various
PC-3 cell lines held in different laboratories to determine
if this will explain the variation in response to RGZ.
In breast cancer, the PPARγ antagonist GW9662 has
recently been used to definitively exclude PPARγ activa-
tion in apoptotic and proliferative responses to selected
PPARγ agonists [24,39]. At a concentration which inhibits
RGZ and TGZ induced adipogenesis in 3T3-L1 cells in our
hands, GW9662 did not reverse the growth inhibitory
effects of TGZ or 15dPGJ2 in any prostate or bladder cell
line examined. Our findings demonstrate that the effects
induced by TGZ and 15dPGJ2 in prostate and bladder car-
cinoma are PPARγ-independent. Whilst these findings are
consistent with PPARγ-independent growth inhibition
observed in some cancer types, it has been clearly demon-
strated in other cases that thiazolidinedione agonists and
15dPGJ2-induced growth inhibition is PPARγ-dependent
[21,25,26,42,43]. In further support of a PPARγ-inde-
pendent mechanism, the TZD ligands and 15dPGJ2 pro-
duced comparable growth inhibition in the TSU-Pr1/TSU-
Pr1-B1/TSU-Pr1-B2 bladder carcinoma series despite
increasing PPARγ expression. Likewise, the levels of PPARγ
expression varied significantly amongst the prostate cell
lines examined and these differing levels did not associate
with the observed growth inhibition.
Further to the PPARγ-independent effects of TGZ and
15dPGJ2 discovered in prostate and bladder carcinoma,
our study also demonstrates that TGZ and 15dPGJ2
induce growth inhibition via different mechanisms. TGZ
induced cell cycle arrest, whilst 15dPGJ2 treatment
resulted in apoptosis. This provides further evidence that
these PPARγ ligands implement unique intracellular sig-
nalling pathways. Recently, TGZ-induced apoptosis in PC-
3 cell lines was shown to involve reduced association of
Bcl-2 and Bcl-xL with Bak, leading to caspase-dependent
apoptosis [15]. The capability of TGZ to induce apoptosis
in this system may be reflective of the larger percentage of
control cells in G2/M phase of the cell cycle. Thus, TGZ
may be able to inhibit the growth of both actively prolif-
erating tumours and tumours with a lower mitotic rate
more typically observed in prostate cancer. The growth
arrest and DNA damage-inducible gene 45 (GADD45) has
been implicated in TGZ-induced apoptosis in breast carci-
noma cell lines [40]. Other potential PPARγ-independent
mechanisms that may induce apoptosis include the gener-
ation of reactive oxygen species [21] and induction of cel-
lular acidosis [39]. Recently, Chintharlapalli et al. [44]
demonstrated that PPARγ agonists induce apoptosis in
colon cancer through PPARγ receptor independent actions
involving early growth response-1 and NSAID-activated-
gene-1.
While treatment with thiazolidinedione ligands has elic-
ited both preventative and deleterious effects in colon and
breast cancer [7,45,46], in prostate cancer certain thiazoli-
dinedione ligands exhibit promising antineoplastic prop-
erties. TGZ inhibits primary prostatic tumour growth in
immunodeficient mice, and in short term culture of
human prostate tissue induces selective necrosis of cancer
cells while sparing the adjacent normal tissue [2]. In addi-
tion, TGZ has been shown to stabilise and reduce PSA lev-
els in clinical trials of patients with advanced prostate
cancer [5,28,29]. The potential clinical utility of TGZ rein-
forces the need to understand the mechanism of action of
various thiazolidinedione and other PPARγ ligands. New
evidence suggests PPARγ may play a role in the differenti-
ation of epithelia [47,48], which is an exciting prospect in
the field of cancer research. Our data indicates RGZ and
PGZ would be useful candidates to study the role of up-
regulated PPARγ in prostate and bladder carcinoma as
these ligands do not exhibit PPARγ-independent growth
inhibitory effects. Our current findings demonstrate that
15dPGJ2 and TGZ induce growth arrest in bladder and
prostate carcinoma cell lines in a PPARγ-independent
manner, and via distinct mechanisms. Further characteri-
sation and elucidation of the molecular mechanisms
underlying the antineoplastic effects of TGZ and 15dPGJ2
will be important for clinical development and utilization
of these agents.
Conclusion
PPARγ is overexpressed in multiple cancer types and the
role of this receptor in carcinoma progression has been
widely studied using the family of high affinity thiazolid-
inedione PPARγ agonists. However, it has recently been
demonstrated that PPARγ ligands can exert PPARγ-inde-
pendent biological responses including growth arrest and
apoptosis in selected carcinoma types. In this paper we
demonstrate not only reduced survival in response to cer-
tain PPARγ ligands, but that these ligands differentially
induce growth arrest or apoptosis in bladder and prostate
cell lines in a PPARγ-independent manner. This studyPage 11 of 13
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BMC Cancer 2006, 6:53 http://www.biomedcentral.com/1471-2407/6/53highlights the need to elucidate the distinct PPARγ-inde-
pendent mechanisms of action of individual PPARγ lig-
ands prior to clinical exploration. Our data also suggests
that in studying the activation of PPARγ, careful consider-
ation should be given to the ligand employed.
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